Clinical aspects and pathophysiology of inflammatory bowel disease

Clinical Microbiology Reviews

Volumn 15, Issue 1, 2002, Pages 79-94

  Hendrickson, Barbara A ^a   Gokhale, Ranjana ^a   Cho, Judy H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; HLA ANTIGEN CLASS 2; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS;

ADOPTIVE TRANSFER; ANIMAL MODEL; ARTHRALGIA; ARTHRITIS; AUTOIMMUNE DISEASE; CLINICAL FEATURE; CROHN DISEASE; DISEASE SEVERITY; ENTERITIS; FEVER; GENE LOCUS; GENETIC LINKAGE; GENOME; HEPATOBILIARY DISEASE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PROGNOSIS; REVIEW; T LYMPHOCYTE;

ADULT; ANIMALS; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED C3H;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 0036141470     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.15.1.79-94.2002     Document Type: Review

References (141)

1. Fluorescent-oligonucleotide probing of whole cells for determinative, phylogenetic, and environmental studies in microbiology
2. Etiology and pathophysiology of inflammatory bowel disease-environmental factors
3. WHO concludes that measles viruses are not associated with Crohn's disease
4. Growth factors in inflammatory bowel disease
5. Genetic epidemiology of inflammatory bowel disease
6. Inflammatory bowel disease in Iceland, 1980-1989. A retrospective nationwide epidemiologic study
7. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease
8. Oxazolone colitis: A murine model of T helper cell type-2 colitis treatable with antibodies to interleukin-4
9. Monozygotic twins with Crohn's disease and ulcerative colitis: A unique case report
10. An immunocytochemical search for infectious agents in Crohn's disease
11. Identification of susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: Evidence for epistasis between 1p and IBD1
12. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's Disease
13. Presence of adherent Escherichia coli strains in the ileal mucosa of patients with Crohn's disease
14. Relationship of extraintestinal involvements in inflammatory bowel disease: New insights into autoimmune pathogenesis
15. Bone and joint diseases in inflammatory bowel disease
16. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis
17. Role of animal models for the pathogenesis and treatment of inflammatory bowel disease
18. High-density genome scan in Crohn's disease shows confirmed linkage to chromosome 14q11-12
19. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
20. Perinatal measles infection and subsequent Crohn's disease
21. Survival and causes of death in patients with inflammatory bowel disease: A population based study
22. Crohn's disease after in-utero measles virus exposure
23. Commensal bacteria as targets in Crohn's disease
24. Experimental models of inflammatory, bowel disease
25. Mycobacterium paratuberculosis and Crohn's disease
26. A case-control study of measles vaccination and inflammatory bowel disease
27. Role of chemokines in inflammation and immunoregulation
28. Measles virus serology in Crbhn's disease
29. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives
30. An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele
31. Disparate CD4+ T lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ whereas ulcerative colitis LP cells manifest increased secretion of IL-5
32. Childhood factors in the pathogenesis of inflammatory bowel disease: An international cooperative study
33. Bone mineral density assessment in children with inflammatory bowel disease
34. Therapeutic strategies for pediatric Crohn's disease
35. Linkage of inflammatory bowel disease to human chromosome 6p
36. A genome-wide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort
37. Inflammatory bowel disease
38. Measles, month of birth, and Crohn's disease
39. Increased type 1 fimbrial expression among Escherichia coli isolates in the murine cecum following catabolic stress
40. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin
41. Role of bacterial intimin in colonic hyperplasia and inflammation
42. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese
43. Etiological role of mycobacterium in Crohn's disease: An assessment of the literature
44. Mapping of a susceptibility locus for Crohn's disease on chromosome 16
45. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
46. Immunohistochemical analysis of the distribution of measles related antigen in the intestinal mucosa in inflammatory bowel disease
47. Human Nod1 confers responsiveness to bacterial lipopolysaccharides
48. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease
49. Antibodies to colonic epithelial cells from the serum and colonic mucosal washings in ulcerative colitis
50. Safety and efficacy of azathioprine (AZA) and 6-mercaptopurine (6-MP) in the treatment of children and adolescents with inflammatory bowel disease
51. Somatomedin-C levels in growth-impaired children and adolescents with chronic inflammatory bowel disease
52. Recent developments in "non-specific" inflammatory bowel disease
53. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies
54. Interleukin-10-deficient mice develop chronic enterocolitis
55. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987
56. Inflammatory bowel disease in 67 families each with three or more affected first-degree relatives
57. Reactivation of arthritis induced by small bowel bacterial overgrowth in rats: Role of cytokines, bacteria, and bacterial polymers
58. The incidence of Crohn's disease is not decreasing in Sweden
59. Immunocytochemical evidence of listeria. Escherichia coli and streptococcus antigens in Crohn's disease
60. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production
61. Primary sclerosing cholangitis is associated with nonsmoking: A case-control study
62. Crohn's disease in Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and survival
63. T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice
64. A genomewide search identifies potential new susceptibility loci for Crohn's disease
65. Chemokines in inflammatory bowel disease
66. Recent developments in the immunology of inflammatory bowel disease
67. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis
68. Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice
69. Histocompatibility antigens in inflammatory bowel disease. Their clinical significance and their association with arthropathy with special reference to HLA-B27(W27)
70. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor
71. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain
72. Extraintestinal manifestations of inflammatory, bowel disease
73. Infections in the immunopathogenesis of chronic inflammatory bowel disease
74. Comparison of clinical features of Crohn's disease and ulcerative colitis with onset in childhood or adolescence
75. Course and prognosis of idiopathic ulcerative proctosigmoiditis in young patients
76. The critical role of interleukin-4 but not interfeon gamma in the pathogenesis of colitis in T-cell receptor α mutant mice
77. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance
78. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice
79. Bioactive IL-18 expression is up-regulated in Crohn's disease
80. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-1987: A sixfold increase in incidence
81. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene
82. Inflammatory bowel disease in African-American children living in Georgia
83. Susceptibility to Crohn's disease by a frameshift mutation in Nod2, resulting in lipopolysaccharide hyporesponsiveness
84. Antineutrophil cytoplamic antibodies in children with inflammatory bowel disease
85. Autoimmunity in ulcerative colitis (UC): A predominant colonic mucosal B cell response against human tropomyosin isoform 5
86. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease
87. Inflammatory bowel disease in a Danish twin register
88. A novel model of inflammatory bowel disease: Mice deficient for the multiple drug resistant gene, mdr1a, spontaneously develop colitis
89. Role of cytokines in the pathogenesis of inflammatory bowel disease
90. Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics
91. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells
92. A critical role for transforming growth factor-β but not interleukin-4 in the suppression of T helper type 1-mediated colitis by CD4Rb low CD4+ T cells
93. Infliximab for the treatment of fistulas in patients with Crohn's disease
94. Hepatobiliary manifestations of inflammatory bowel disease
95. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease
96. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats
97. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli
98. Search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci
99. Surgical stress shifts the intestinal Escherichia coli population to that of a more adherent phenotype: Role in barrier regulation
100. The epidemiologic and demographic characteristics of inflammatory bowel disease: An analysis of a computerized file of 1400 patients
101. Titres of anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity
102. Smoking and inflammatory bowel disease
103. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease
104. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
105. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene
106. Childhood exposure to environmental tobacco smoke and the risk of ulcerative colitis
107. Current concepts of etiology and pathogenesis of ulcerative colitis and Crohn's Disease
108. Review article: Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis
109. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease
110. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12
111. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls
112. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin12/signal transducer and activator of transcription (Stat)-4 pathway but is not conditional on interferon-γ expression by T cells
113. A common functional polymorphism (C→A substitution at position -863) in the promoter region of the turmour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha
114. Adult coeliac disease and cigarette smoking
115. HLA-DR and -DQ phenotypes in inflammatory bowel disease: A meta-analysis
116. The pathogenesis of mucosal inflammation in murine models of inflammatory bowel disease and Crohn disease
117. Concordance rates of twins and siblings in inflammatory bowel disease (IBD)
118. Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice
119. Identification of a novel bacterial sequence associated with Crohn's disease
120. Escherichia coli antibodies in patients with inflammatory bowel disease
121. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils
122. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
123. The case for an infectious etiology
124. Controlled trial of antituberculous chemotherapy in Crohn's disease: A five year follow up study
125. Incidence of Crohn's disease in Cardiff over 60 years. 1986-1990. An update
126. The role of mycobacteria in Crohn's disease
127. Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis
128. Longterm outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn's disease
129. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins: A study of heritability and the influence of smoking
130. Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis
131. Immunotherapy of Crohn's disease
132. Lack of support for a common etiology in Johne's disease of animals and Crohn's disease in humans
133. Immunogenetic aspects of primary sclerosing cholangitis: Implications for therapeutic strategies
134. An open label pilot study of low dose thalidomide in chronically active, steroid dependent Crohn's disease
135. Crohn's disease: Pathogenesis and persistent measles virus infection
136. Crohn's disease: The case for measles virus
137. Absence of Escherichia coli. Listeria monocytogenes and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues
138. Chronic intestinal inflammation in STAT-4 transgenic mice: Characterization of disease and adoptive transferr by TNF-plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens
139. Effect of fecal diversion alone on perianal Crohn's disease
140. Familial empirical risks for inflammatory bowel disease: Differences between Jews and non-Jews
141. Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses